Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GRAALL 2024 frontline immunotherapy and allogeneic HSCT study in adult acute lymphoblastic leukemia
2024-511437-35-00Phase 3Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- May 2025
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 3
01
Overview
Phase 3, randomised trial of blinatumomab, ponatinib and isatuximab in acute lymphoblastic leukemia (ALL) and T-lymphoblastic lymphoma (T-LBL) (3 cohorts), sponsored by Assistance publique - Hôpitaux de Paris. Planned start May 2025; status: authorised.
02
Drugs
blinatumomabponatinibisatuximab
03
Conditions
acute lymphoblastic leukemia (ALL)T-lymphoblastic lymphoma (T-LBL)
Beyond the preview
Go deeper on 2024-511437-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511437-35-00.